SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.17+1.9%9:58 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: AurumRabosa who wrote (1051)5/3/2000 9:09:00 PM
From: david james  Read Replies (1) of 52153
 
A lot of companies including CEGE will be presenting at this meeting. Should be good for the sector.

____________________________________________________
IMPORTANT ADVANCES IN CANCER RESEARCH TO BE PRESENTED AT THE ASCO 2000 ANNUAL MEETING

-- ASCO Announces Press Program for Meeting in New Orleans, LA, May 20-23, 2000 --

-- Meeting Features New Developments in Breast Cancer Therapy, Treating Hot Flashes, and Molecular Treatment Strategies --

More than 20,000 cancer professionals from around the world will gather at the 36th Annual Meeting of the American Society
of Clinical Oncology (ASCO) at the Ernest N. Morial Convention Center in New Orleans from May 20-23, 2000.

ASCO?s Plenary Session will feature important breakthroughs in breast, lung, kidney, and stomach cancers, as well as a new,
non-estrogenic drug to reduce hot flashes. ASCO press conferences will highlight new findings in the treatment of breast
cancer, efforts to improve quality of life for cancer patients, new molecular targets and strategies for cancer treatment, advances
in lung cancer care, and the results of major, practice-changing, clinical trials.

In addition, ASCO President, Joseph S. Bailes, MD, will discuss the society?s major new initiative to assess the quality of
cancer care in the U.S., and ASCO will hold a special session for media to address the current state of clinical cancer research ?
including cost, safety and recent developments in high-dose chemotherapy for breast cancer.

Over 2,600 abstracts have been accepted this year, more than ever before, for presentation in the plenary, integrated, oral, poster
and general poster sessions, and for publication in the program proceedings book. Scientific research will be presented on each
of the four days of the meeting, in addition to physician education sessions.

PRESS PROGRAM

Beginning Saturday, May 20th, ASCO will hold seven media briefings featuring significant research being presented at the
Annual Meeting, and reviewing important areas of concern in the field of cancer care. All research is embargoed until the date
and time of scientific presentation.


asco.org
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext